Tremelimumab Plus Durvalumab Bests Sorafenib OS Rates In Frontline HCC Treatment
Arndt Vogel, MD, PhD, discusses a post-hoc analysis of the phase 3 HIMALAYA trial which found tremelimumab plus durvalumab to be superior to sorafenib in improving overall survival.
Targeting KRAS Mutations May Help Address Unmet Need in Pancreatic Cancer Treatment
An expert of gastrointestinal oncology with the Henry Ford Cancer Institute discusses the developing presence of targeted treatments in the pancreatic cancer treatment paradigm.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512